One To Watch

Ocular Therapeutix

A USA-based ophthalmology company focused on drug delivery and long-acting therapies for eye disease. The company’s development activities are centered in the United States, with clinical programs that include multi-country study sites for lead retina trials.

Founding and History

Ocular Therapeutix was founded in 2006 and is publicly traded on Nasdaq under ticker OCUL. The company has a marketed product in the U.S. and has repositioned its R&D focus toward retina, with a lead program in registrational development for wet age-related macular degeneration.

Therapy Areas and Focus

Ocular Therapeutix is focused on ophthalmology, with current emphasis on:

Retina: wet age-related macular degeneration and diabetic retinopathy
Glaucoma: sustained intraocular pressure reduction via an injectable approach
Ocular surface and post-surgical inflammation: via an approved corticosteroid insert

Technology Platforms and Modalities

Ocular Therapeutix’s core platform is a bioresorbable hydrogel drug-delivery technology (ELUTYX) designed for prolonged, local delivery of small molecules in ocular tissues. Key modalities include:

Sustained-release intravitreal hydrogel delivery for retinal disease (AXPAXLI, also referred to as OTX-TKI; axitinib intravitreal hydrogel)
Sustained-release intracameral hydrogel delivery for glaucoma (OTX-TIC; travoprost intracameral hydrogel)
Intracanalicular insert delivery for corticosteroids (DEXTENZA; dexamethasone ophthalmic insert)

Key Personnel

Pravin U. Dugel, Executive Chairman, President, and CEO
Donald Notman, Chief Financial Officer and Chief Operating Officer
Jeffrey S. Heier, Chief Scientific Officer
Nadia K. Waheed, Chief Medical Officer
Peter K. Kaiser, Chief Development Officer
Peter Jarrett, Chief Technical Officer
Sanjay Nayak, Chief Strategy Officer
Namrata Saroj, Chief Business Officer
Steve Meyers, Chief Commercial Officer
Todd Anderman, Chief Legal Officer and Corporate Secretary
Barry Rubenstein, Chief Human Resources Officer
Art Ciociola, Chief Regulatory and Quality Officer
Chad Clatterbaugh, Chief of Staff

Strategic Partnerships

Ocular Therapeutix’s strategy is primarily platform- and trial-execution driven, with value inflection tied to late-stage clinical outcomes in retina. The company’s most visible external dependencies are typical for an ophthalmology developer: clinical-site networks, manufacturing and supply-chain execution for injectable products, and regulatory alignment for registrational trial design.

FAQ Section

Ocular Therapeutix develops ophthalmic therapies built around a bioresorbable hydrogel platform (ELUTYX) intended to deliver drugs locally over extended periods. The company applies this approach across different compartments of the eye depending on the indication, including intravitreal delivery for retina and intracameral delivery for glaucoma.

The company is focused on ophthalmology, with current pipeline priorities in retinal vascular disease (wet AMD and diabetic retinopathy) and glaucoma. It also markets a U.S. product for ocular inflammation and pain following ophthalmic surgery, and for ocular itching associated with allergic conjunctivitis.

AXPAXLI (axitinib intravitreal hydrogel; OTX-TKI) is in Phase III clinical development for wet AMD and diabetic retinopathy, with registrational trial programs designed around durability and reduced injection frequency.

OTX-TIC (travoprost intracameral hydrogel) is in Phase II clinical development for glaucoma, positioned as a long-acting injectable intended to reduce and maintain intraocular pressure.

DEXTENZA (dexamethasone ophthalmic insert) is an approved product in the U.S.

In 2025, the company reported progress in its Phase III wet AMD program for AXPAXLI, including completing enrollment/randomization targets in a registrational study (SOL-R) ahead of schedule. The company has also continued to communicate Phase III program structure across wet AMD and diabetic retinopathy, including parallel registrational designs intended to support filing pathways if study outcomes are supportive.

Public disclosures emphasize Phase I results as the foundation for advancing AXPAXLI into Phase III and outline registrational endpoints focused on durability and disease control in wet AMD and diabetic retinopathy. Detailed datasets are typically communicated in scientific or investor settings rather than as routine site-level summaries.

Key regulatory-facing milestones are tied to completion and readout of Phase III registrational studies for AXPAXLI in wet AMD and diabetic retinopathy and subsequent filing planning. For glaucoma, milestones relate to Phase II execution and decisions on the next-stage development path for OTX-TIC.

Ocular is led by an ophthalmology-focused executive and clinical leadership group with senior roles held by practicing or formerly practicing retina specialists and experienced development executives. The organization is structured around late-stage clinical execution in retina, paired with platform-based product development and commercial operations for its marketed product.

Want to Update your Company's Profile?